Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)

NCT05495295 is registered in ClinicalTrials.gov with Phost'In Therapeutics as lead sponsor.

NCT NCT05495295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05495295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)
Lead sponsor
Phost'In Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 18, 2022
Completion date
July 31, 2027
Enrollment
149 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, glioblastoma multiforme, malignant tumor, metastatic cancer